Disturbed sleep-wake cycle and circadian rhythmicity are associated with cancer, but the underlying mechanisms are unknown. Employing a tissue-isolated human breast xenograft tumor nude rat model, we observed that glycogen synthase kinase 3␤ (GSK3␤), an enzyme critical in metabolism and cell proliferation/survival, exhibits a circadian rhythm of phosphorylation in human breast tumors. Exposure to light-at-night suppresses the nocturnal pineal melatonin synthesis, disrupting the circadian rhythm of GSK3␤ phosphorylation. Melatonin activates GSK3␤ by inhibiting the serine-threonine kinase Akt phosphorylation, inducing ␤-catenin degradation and inhibiting epithelial-to-mesenchymal transition, a fundamental process underlying cancer metastasis. Thus, chronic circadian disruption by light-at-night via occupational exposure or age-related sleep disturbances may contribute to cancer incidence and the metastatic spread of breast cancer by inhibiting GSK3␤ activity and driving epithelial-to-mesenchymal transition in breast cancer patients. (Molecular Endocrinology 26: 1808 -1820, 2012) 
graded by a destruction complex consisting of axin, adenomatous polyposis coli, glycogen synthase kinase 3␤ (GSK3␤), and casein kinase 1 (CK1) (5) . Activated GSK3␤ phosphorylates ␤-catenin triggering its ubiquitin/ proteosome-mediated degradation. Inhibition of GSK3␤ by either serine-threonine kinase Akt or Wnt signaling stabilizes ␤-catenin, promoting its nuclear translocation and dimerization with TCF/LEF to induce the transcription of Wnt target genes (5) . Interestingly, Snail, the Ecadherin repressor, can be regulated by GSK3␤-mediated ubiquitination similar to ␤-catenin (8) . These findings put GSK3␤ as a focal point in the EMT signaling pathway due to its ability to regulate both Snail and ␤-catenin.
Numerous endocrine factors have been shown to influence the development and growth of breast cancer, including steroid hormones, growth factors (9, 10) , and melatonin (MLT) (11) , an indoleamine hormone synthesized and secreted by the pineal gland in the dark phase of the light-dark cycle (12) . Pineal production of MLT is suppressed by light, thus the blood levels of MLT are low during the day and high during the night (12) . The nocturnal surge of MLT acts as a biological timing signal driven by a central pacemaker residing in the suprachiasmatic nuclei (SCN) (13, 14) and is acutely suppressed by exposure to light during the night (12, 13) . At physiological concentrations, MLT appears to be involved in the regulation of a wide range of biological and pathological processes (12, 14) . It has been well established that MLT exerts an antiproliferative effect in human breast cancer cells in vitro (15) and inhibits the growth of mammary tumors in animal models (11, 16) . The antiproliferative effect of MLT appears to be mediated primarily through the MLT receptor 1A (MT 1 ), a G protein-coupled receptor (17) . Recently, we (18) , and others (19) , have demonstrated that MLT also has antiinvasive properties in human breast cancer cells. The antiinvasive action of MLT is mediated, partially, through inhibition of p38 MAPK and its downstream regulation of matrix metalloproteinase (MMP)2 and MMP9 (18) . In addition, MLT's effect on breast cancer cell invasion/metastasis appears to involve its regulation of E-cadherin and ␤-integrin (19) .
To determine whether MLT regulates EMT to affect breast cancer cell invasion, we examined its actions on GSK3␤ and EMT. Using a tissue-isolated human breast xenograft tumor nude rat model (20) , we demonstrated that MLT activates GSK3␤ by inhibiting Akt phosphorylation and activity, blocking Akt-mediated phosphorylation and inactivation of GSK3␤. Up-regulation of GSK3␤ signaling by MLT leads to reduced levels of active ␤-catenin, and repression of ␤-catenin-mediated transactivation, which subsequently restores E-cadherin expression and represses vimentin expression in human breast cancer cells with an EMT phenotype. Collectively, these data suggest that MLT plays an important role in the regulation of EMT in breast cancer. Moreover, using the same tissue-isolated human breast xenograft tumor nude rat model, we demonstrated that the inactive form (phosphorylated at Ser 9 ) of GSK3␤ exhibits a circadian rhythm in human breast tumors. Exposure to light-at-night, which suppresses the nocturnal MLT synthesis, disrupts the circadian rhythm of GSK3␤ phosphorylation. These findings have provided a potential mechanism linking circadian disruption with cancer.
Materials and Methods

Chemicals and reagents
All chemicals and tissue culture reagents were purchased from Sigma-Aldrich (St. Louis, MO). Cell culture medium, DMEM, RPMI 1640, and fetal bovine serum (FBS) were purchased from GIBCO (now part of Invitrogen Corp., Carlsbad, CA). The FuGENE HD transfection reagent was purchased from Roche (Indianapolis, IN). Human recombinant IGF-I and Wnt3a were purchased from PeproTech, Inc. (Rocky Hill, NJ). Human recombinant TGF-␤ was purchased from R&D Systems (Minneapolis, MN).
Cell lines and cell culture
Three human breast cancer cell lines were used in these studies. The parental MCF-7 human breast cancer cell line was obtained from the laboratory of the late William L. McGurie (San Antonio, TX). The MCF-7/steroid receptor-negative (SR Ϫ ) human breast cancer cell line was established from SR Ϫ tumors that evolved over several passages from a subset of MCF-7 xenografts that had become estrogen unresponsive (20) . MCF-7/constitutively active Src (caSrc) cell line (stably transfected with caSrc kinase) was kindly provided by Bin Shan (Tulane University). All cell lines, except MCF-7/caSrc cells, were cultured in RPMI 1640 medium supplemented with 10% FBS (GIBCO), 50 mM minimum essential medium nonessential amino acids, 1 mM sodium pyruvate, 2 mM glutamine, 10 mM basal medium eagle, 100 mg/ml streptomycin, and 100 U/ml penicillin. The MCF-7/caSrc cells were cultured in DMEM with the same supplements as described above. These cell lines were routinely maintained at 37 C in a humidified atmosphere of 5% CO 2 and 95% air.
Protein extraction and Western blot analysis
Cells were harvested and then lysed in a protein extraction buffer containing Tris [50 mM (pH 7.4)], EDTA (20 mM), Nonidet P-40 (0.5%), NaCl (150 mM), phenylmethylsulfonyl fluoride (0.3 mM), NaF (1 mM), Na 3 VO 4 (1 mM), dithiothreitol (1 mM), aprotinin (1 g/ml), leupeptin (1 g/ml), and pepstatin (1 g/ml). The cell lysates were centrifuged for 10 min at 10,000 ϫ g at 4 C. Protein concentrations of the supernatants were determined using a protein assay kit (Bio-Rad Laboratories, Inc. Hercules, CA). Total protein (80 g per sample) was electrophoretically separated on a 10% SDS-PAGE and electroblotted onto a Hybond membrane. After incubation with 5% nonfat milk in 
Tumor lysate extraction
Frozen tumors were pulverized and manually homogenized in 50 mM HEPES (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.1% sodium deoxycholate, 1 mM Na 3 VO 4 , 100 nM okadaic acid, and 1ϫ protease inhibitor cocktail Set I (Calbiochem/EMD Biosciences, Billerica, MA). Tumor lysates were centrifuged at 15,300 ϫ g for 20 min. Supernatants were aliquoted and stored at Ϫ80 C.
Immunofluorescence staining
MCF-7 cells were seeded in four-well chamber slides at a density of 4 ϫ 10 4 cells/well and transiently transfected with the pcDNA3.1-MT 1 MLT receptor DNA construct. Sixteen hours after transfection, cells were subjected to serum starvation for 24 h. Cells were then pretreated with MLT (10 Ϫ8 M) for 30 min before incubation with MLT and TGF-␤ (10 ng/ml) for an additional 48 h. After incubation cells were fixed with 4% paraformaldehyde in PBS for 10 min at room temperature, permeabilized with 0.3% Triton X-100 in PBS/5% normal goat serum for 1 h, and incubated overnight with anti-E-cadherin antibody (Cell Signaling Technology, Inc.). The secondary antibody used was Alexa Fluor 488 goat antirabbit secondary antibody (Molecular Probes, Grand Island, NY).
Fluorescence images were acquired using a Nikon Eclipse 80i microscope and a SensiCam QE camera (Cooke Corp., Romulus, MI) and IPLab version 3.65a software (Scanalytics, Rockville, MD). Exposure conditions were optimized for the brightest field of the specified conditions and held constant for subsequent exposures.
Transient transfection
MCF-7 cells were seeded in six-well plates at a density of 3 ϫ 10 6 cells per well in RPMI 1640 supplemented with 10% FBS. After 24 h of serum starvation, cells were then transfected with 0.7 g of super-pTOPFLASH (8 ϫ TCF/LEF binding sites) or pFOPFLASH (8 ϫ mutant TCF/LEF binding sites) luciferase reporter construct (provided by Gill Morris at Tulane University; originally from Randall Moon at University of Washington, Seattle, WA) and 1.0 g of pcDNA3-␤-catenin, pcDNA3.1-MT 1 , or empty vector, using the FuGENE HD transfection reagent according to the manufacture's instructions.
Luciferase reporter assays
TOP/FOPFLASH luciferase activities present in cellular lysates were assayed using the Luciferase Assay System (Promega, Madison, WI) according to the manufacture's instructions and were normalized with ␤-galactosidase activities.
Wound healing assays
The migratory property of MCF-7/SR Ϫ cells was examined using the CytoSelect Wound Healing Assay kit (Cell Biolabs, San Diego, CA) according to the manufacture's instructions. Briefly, cell suspension was added to the well with a plastic insert in place. The insert was removed from the well after a monolayer of cells formed, creating a wound gap of 0.9 mm. Cells were then treated with MLT (10 Ϫ8 M) or vehicle and incubated for another 48 h.
Transwell cell migration assay
MCF-7/SR
Ϫ cells in log phase of growth were serum-starved for 24 h before seeding, detached by brief trypsinization, and resuspended in medium containing the appropriate treatment. Cells (4 ϫ 10 5 cells/ml in 0.5 ml of medium supplemented with 0.5% BSA) were added in suspension to the upper chamber of the inserts (Becton Dickinson Biosciences), and medium (0.75 ml, supplemented with 10% FBS as chemoattractant) containing the same treatment was added to the bottom well. After incubation for 24 h, the nonmigrating cells were removed from the upper surface of the membrane, and cells migrated to the under surface of the membrane were stained with a Diff-Quick staining kit (Dade Behring, now part of Siemens Healthcare Diagnostics, Deerfield, IL) and counted microscopically at ϫ100 magnification. Five fields per membrane were randomly selected and counted in each group.
Collection of MLT-supplemented human donor whole blood and tissue-isolated tumor perfusions in situ
Three healthy premenopausal female volunteers (mean age, 22.6 Ϯ 0.6 yr) were recruited at Tulane University, regardless of race and ethnic background. All subjects were on regular sleep patterns and were free of any medication (MLT supplements, birth control pills, and/or ␤-blockers). All subjects signed approved institutional review board consent forms. Antecubital venous blood was drawn from each female subject during the daytime both before and after an oral MLT supplement of 300 g, which results in pharmacologic blood levels 1 h after administration. MCF-7/SR Ϫ xenografts were implanted in nude rats in a tissue-isolated manner as previously described (20) . Sets (three tumors per perfusion) of tissue-isolated MCF-7/SR Ϫ human breast cancer xenografts were perfused in situ for 1 h as previously described (20) with whole blood collected from donor human subjects either before or after MLT supplement.
Circadian rhythm of GSK3␤ phosphorylation and Snail expression and disruption by light-at-night
Weanling female nude rats (Hsd:RH-Foxn1 rnu ) between 35 and 50 g were housed in light exposure chambers on a 12-h light, 12-h dark (12L:12D) cycle [lights on 0600 -1800 h, i.e. Zeitgeber time (ZT)0 -ZT12] as previously described (21) . Animals were allowed to acclimate for 2 wk and then separated into two groups of 36 animals each. Group A (control) remained on a 12L:12D (total darkness) lighting regimen. Group B (lightat-night) were subjected to 12L:12L with a light intensity of 0.2 lux or 0.08 W/cm 2 present at night. Two weeks later, MCF-7/SR Ϫ human breast cancer xenografts were implanted into these animals in a tissue-isolated manner, as described previ-ously (20) . When tumors reached sufficient size for measurement, six tumors were collected at 4-h interval time points over a 24-h period (ZT2, ZT6, ZT10, ZT14, ZT18, and ZT22). Tumor lysates were assayed for phospho-GSK3␤ and Snail by Western blot analysis.
Nocturnal light exposure studies in human subjects and effects on Akt and GSK3␤ phosphorylation
At Thomas Jefferson University, healthy male volunteers (n ϭ 3; mean age, 26.3 Ϯ 4.0 yr) were recruited, regardless of race and ethnic background. All subjects were on regular sleep patterns and were free of any medication (MLT supplements and/or ␤-blockers). All subjects signed approved institutional review board consent forms. Antecubital venous blood sample was drawn from each subject during the daytime (1000 -1400 h), nighttime (0200 h) after 2 h of complete darkness, and nighttime (0330 h) after 90 min of ocular, bright, white light exposure at 580 W/cm 2 (i.e. 2800 lux) at eye level reflected from the wall. Sets (two tumors per perfusion) of tissue-isolated PC3 human prostate cancer xenografts were perfused in situ for 1 h as previously described (20) with these donor blood samples.
Assay of blood hormone levels in rats and human subjects
Rat serum MLT levels were measured via RIA as previously described (20) .
Statistical analysis
Data are represented as the mean Ϯ SEM. The statistical significance at 95% confidence level was determined by one-way ANOVA followed by a Student-Newman-Keuls post hoc test analysis using Statview software (SAS Institute, Inc., Cary, NC).
Results
MLT activates GSK3␤ by blocking Akt-repression of GSK3␤ activity
To determine whether MLT regulates EMT to affect breast cancer cell invasion, we examined its actions on GSK3␤. The kinase activity of GSK3␤ requires phosphorylation at Tyr 216 in the activation loop (22) . Akt inhibits GSK3␤ activity by phosphorylation of GSK3␤ at Ser 9 (23). Dauchy et al. (24) and others (25) reported that MLT can repress Akt activity in a variety of human malignancies. We employed an in vivo model to examine MLT's effect on Akt (26) , in which tissue-isolated MCF-7/SR Ϫ human breast tumor xenografts were perfused in situ for 1 h with daytime (low MLT) human donor blood collected from female human subjects either before or after receiving an oral MLT supplement (Fig. 1A) . Figure  1B shows that Akt phosphorylation at Ser 473 was almost completely abolished in tumors perfused with the postsupplement MLT-rich human donor blood as compared with those perfused with the corresponding MLT-deficient presupplement daytime human blood. The Thr 308 -phosphorylation signal of Akt was very low but was also decreased in tumors perfused with the postsupplement blood (Fig. 1B) . We also examined the effect of MLT on other signaling pathways, including Erk1/2 and p38 MAPK pathways. As shown in Fig. 1C , phosphorylation of Erk1/2, like that of Akt, was dramatically suppressed in tumors perfused with the postsupplement MLT-rich human blood as compared with the presupplement group. However, MLT supplementation did not have any significant effect on the phosphorylation of p38 MAPK, which has been previously shown to be down-regulated by MLT in human breast cancer cells (Fig. 1C) (18) .
Because MLT inhibits Akt phosphorylation, follow-up studies examined whether MLT could block Akt's repressive phosphorylation of GSK3␤. As shown in Fig. 2A , phosphorylation of GSK3␤ at Ser 9 (inactivating phosphorylation site) was significantly repressed after MLT administration in parental MCF-7 (SR ϩ ) cells, whereas the Tyr 216 phosphorylation (activating phosphorylation site) was enhanced. Figure 2B shows that IGF-I stimulated Akt phosphorylation in MCF-7 cells, inducing a concurrent increase in GSK3␤ phosphorylation (Ser 9 ), and that a 30-min pretreatment with MLT blocked IGF-I-mediated Akt phosphorylation of GSK3␤. Employing our in vivo tissue-isolated MCF-7/SR Ϫ human breast tumor xenograft model system, an even more pronounced suppression of GSK3␤ phosphorylation at Ser 9 was observed in tumors perfused with the postsupplement MLT-rich human donor blood compared with tumors perfused with the MLT-deficient presupplement blood from the same female subject (Fig. 2C) .
GSK3␤ activity has been reported to be repressed by the Wnt pathway allowing accumulation of cytoplasmic/ nuclear ␤-catenin (5, 27) . In MCF-7 cells, administration of recombinant human Wnt3a stimulated Akt phosphorylation at Ser 473 and induced GSK3␤ phosphorylation at Ser 9 ( Fig. 2D) . Pretreatment of MCF-7 cells with MLT abolished the actions of Wnt3a (Fig. 2D ) on GSK3␤ phosphorylation, demonstrating that MLT can block both Akt-and Wnt-induced repression of GSK3␤ activity.
MLT activation of GSK3␤ leads to repression of ␤-catenin
To address whether MLT activation of GSK3␤ further leads to down-regulation of ␤-catenin, we examined the effect of MLT on ␤-catenin expression and transcriptional activity. Figure 3A shows that MLT administration induced a rapid reduction in the levels of both active (nonphosphorylated) and total ␤-catenin in MCF-7 cells. Decreased levels of total ␤-catenin were also observed in vivo in tissue-isolated MCF-7/SR Ϫ tumor xenografts per-fused with the postsupplement MLT-rich human donor blood, as compared with the corresponding presupplement group (Fig. 3B) . Next, we examined the effect of MLT on the TCF/LEF-driven transcription using a TOP-FLASH luciferase reporter assay. MLT administration significantly repressed basal transcriptional activity as well as the ␤-catenin-induced TOPFLASH activity in MCF-7 cells (Fig. 3C ). The effect of MLT on TCF/LEFdriven transcription was substantially enhanced by overexpression of the MT 1 receptor. As shown in Fig. 3C , ␤-catenin-induced TOPFLASH activity was almost completely abolished in cells transfected with the MT 1 receptor and treated with MLT (Fig. 3C ).
MLT blocks EMT in human breast cancer cells
To determine whether MLT regulates EMT phenotypes, we first examined its effect on the expression of commonly used epithelial marker E-cadherin and mesenchymal marker vimentin. The effect of MLT administration on E-cadherin and vimentin expression was examined in MCF-7/caSrc cells that were stably transfected with the caSrc kinase and exhibit low E-cadherin and elevated vimentin expression (28) . Protein expression levels of E-cadherin were significantly increased, and vimentin expression was almost completely abolished ( (Fig. 4, C and D) .
GSK3␤ phosphorylation at Ser 9 is circadianregulated and disrupted by light-at-night
Approximately 15-20% of all mammalian genes are under circadian control, including a number of cancer associated genes, and the expression of a number of these genes is modified by light-at-night (29) . Given that GSK3␤ phosphorylation is regulated by MLT, an output of the SCN (central pace maker), we further investigated whether there are circadian-dependent changes in the expression/phosphorylation of GSK3␤. Breast cancer cells grown in culture lack central circadian regulation; thus, we employed our tissue-isolated tumor xenograft model system to examine whether GSK3␤ expression/phosphorylation is circadian-regulated and whether this circadian regulation can be disrupted by the host's exposure to light-at-night. Tissue-isolated MCF-7/SR Ϫ tumor xenografts in nude rats housed under a control 12L:12D cycle Daytime venous blood was drawn from three females both before (Ϫ) and after (ϩ) an oral MLT supplementation of 300 g, which results in pharmacologic blood levels 1 h after administration. Separate sets of three tissue-isolated MCF-7/SR Ϫ xenografts were perfused with pre-or postsupplement blood for 60 min. Western blot analyses examined the phosphorylation of Akt (B) and Erk1/2 and p38 (C). p-, Phospho; t-, total-.
or exposed to light-at-night (12L:12L, with a light intensity of 0.20 lux present at night) were sampled at 4-h intervals over a 24-h period starting at ZT2 (i.e. 2 h after lights on). In control tumors, GSK3␤ phosphorylation at Ser 9 exhibited a circadian rhythm with peak levels at midlight phase (ZT6) when MLT levels are low (1 Ϯ 0.0 pg/ ml) falling gradually to its nadir around middark phase (ZT18) when MLT levels are highest (84 Ϯ 6.0 pg/ ml) (Fig. 5, A-C) . In contrast, circadian disruption by exposure to light-atnight almost completely abolished the nocturnal MLT surge (9.6 Ϯ 0.3 pg/ml at ZT18) (Fig. 5C ) and dysregulated the circadian rhythm of GSK3␤ phosphorylation (Fig. 5, A and B) , resulting in dark phase levels of Ser 9 -phosphorylated GSK3␤ equivalent to the daytime high levels.
We also examined the expression of the ␤-catenin-driven, EMT-associated gene Snail as a readout of circadian regulation of GSK3␤ in these tissue-isolated tumor xenografts. As shown in Fig. 6 , expression of Snail protein also exhibited a very pronounced circadian rhythm with peak levels detected during the dark phase and lower levels during the daytime. Furthermore, Snail expression was constitutively elevated in response to the host's exposure to light-at-night.
Exposure to light-at-night in human male subjects affects Akt and GSK3␤ phosphorylation in human prostate tumors
To address whether light-at-nightinduced disruption of MLT's circadian rhythm is of biological consequence, we collected human donor blood from male human subjects during the daytime, when MLT levels are low, the nighttime, when MLT levels are high, and the nighttime after 90-min ocular exposure to bright, white light (lightat-night). Tissue-isolated PC3 human prostate cancer xenografts were perfused with blood drawn under these different conditions (daytime, nighttime, and light-at-night), and tumor lysates were assayed for phosphorylation of Akt and GSK3␤. As shown in Fig. 7 , tumors perfused with blood drawn during the nighttime exhibited significantly reduced levels of phospho-Akt and GSK3␤ at its
FIG. 2. MLT activates GSK3␤ in human breast cancer cells. A, Regulation of GSK3␤
phosphorylation by MLT in MCF-7 human breast cancer cells. Cells were treated with MLT for the times indicated and Western blot analyses used to examine GSK3␤ phosphorylation at Ser 9 and Tyr 216 . The band intensity of phospho-GSK3␤ was quantified and normalized to that of total-GSK3␤. The data are expressed as percent phospho-GSK3␤ (ratio of phospho-GSK3␤ to total-GSK3␤). n ϭ 3; *, P Ͻ 0.05; **, P Ͻ 0.001 (ANOVA with Student-Newman-Keuls post hoc test). Data are mean Ϯ SEM. B, MLT (30-min pretreatment 10 Ϫ8 M) blocked IGF-I (50 ng/ml)-induced GSK3␤ phosphorylation in MCF-7 cells. The band intensity of phospho-Akt and phospho-GSK3␤ was quantified and normalized to that of total-Akt and total-GSK3␤, respectively. The data are expressed as percent phospho-Akt and phospho-GSK3␤. n ϭ 3; *, P Ͻ 0.05; ***, P Ͻ 0.0001 (ANOVA with Student-Newman-Keuls post hoc test). Data are mean Ϯ SEM. C, MLT-rich postsupplement human blood suppressed GSK3␤ phosphorylation at Ser 9 in tissue-isolated MCF-7/SR Ϫ human breast cancer xenografts. D, MLT (30-min pretreatment 10 Ϫ8 M) blocked the inhibitory effect of Wnt3a (200 ng/ml) signaling on GSK3␤ in MCF-7 cells. Ctrl, 0.00001% ethanol; p-, phospho-; t-, total-. Mol Endocrinol, November 2012, 26(11):1808 -1820 mend.endojournals.orgSer 9 inhibitory site as compared with those perfused with daytime blood. The inhibitory effect of the nighttime blood on Akt and GSK3␤ phosphorylation was reversed in tumors perfused with nighttime blood drawn from male subjects exposed to light-at-night.
Discussion
GSK3␤ is a ubiquitously expressed protein kinase that acts as a key regulator in the signaling networks that govern EMT (5). Unlike most other protein kinases, GSK3␤ is constitutively active, and its activity is inhibited upon cellular responses to stimuli, such as growth factors (5 (Fig. 1) , resulting in blockade of GSK3␤ phosphorylation at Ser 9 (Fig. 2C ). These in vivo results were further confirmed by in vitro studies using parental SR ϩ MCF-7 cells, in which MLT induces a gradual decrease in the Ser 9 -phosphorylation of GSK3␤ ( Fig. 2A) . In addition, we observed a modest increase in GSK3␤ phosphorylation at Tyr 216 (the activating phosphorylation) in response to MLT administration in MCF-7 cells (Fig. 2A) . Collectively, these results demonstrate that MLT suppresses Akt phosphorylation/activity and up-regulates GSK3␤ activity and signaling by inhibiting its Ser 9 -phosphorylation while stimulating the Tyr 216 phosphorylation.
To test whether MLT regulates other signaling pathways, we also examined the effect of MLT on the phosphorylation of Erk1/2 and p38 MAPK using the tissueisolated tumor perfusion model. Levels of phosphoErk1/2 were significantly suppressed by the postsupplement MLT-rich human blood (Fig. 1C) . In contrast, p38 phosphorylation was not affected by MLT supplementation, indicating that in vivo MLT specifically regulates phosphorylation of Akt, GSK3␤ and Erk1/2 in the tissue-isolated MCF-7/SR Ϫ xenografts in nude rats.
Previously, we have reported that MLT suppresses p38 phosphorylation in human breast cancer cells in vitro (18) . The discrepancy between the current study on p38 and our previous report may be caused in part by cell line variance (MCF-7/SR Ϫ vs. MCF-7/6 cells) and that MLT's action on p38 is cell-context dependent. Furthermore, tumor cells in a circadian-regulated environment (in a circadian complete host) are differentially modulated by MLT compared with noncircadian-regulated cells in long-term culture (30) .
In line with the in vitro and in vivo results on MLT regulation of Akt and GSK3␤, MLT administration was able to block IGF-I-induced Akt phosphorylation in MCF-7 cells and prevent the concurrent stimulation of GSK3␤ phosphorylation at Ser 9 (Fig. 2B) . Thus, MLT inhibits Akt phosphorylation and attenuates Akt's repressive action on GSK3␤, allowing GSK3␤ activation. Interestingly, the Wnt signaling pathway has been shown to cross talk with the Akt pathway to regulate GSK3␤ (27, 31) . In our study, we observed an induction of Akt phosphorylation and concomitant increase in Ser 9 -phosphorylation of GSK3␤ in MCF-7 cells upon Wnt3a stimulation, which is indicative of a cross talk between the Wnt and Akt signaling pathways (Fig. 2D) . The effects of Wnt3a on Akt and GSK3␤ were blocked by MLT administration (Fig. 2D) , demonstrating that MLT can block both Akt-and Wntinduced phosphorylation/repression of GSK3␤ activity (Fig. 8) . Further studies are needed to determine whether MLT can modulate the canonical Wnt signaling involving activation of the Frizzled receptors to control GSK3␤ localization and thus accessibility to its substrates (5) .
Recently, a new mechanism of GSK3␤ regulation was proposed. The p38 MAPK was shown to inactivate GSK3␤ by inducing an inhibitory phosphorylation at Ser 389 (32) . We ruled out the possibility of implication of p38 in MLT regulation of GSK3␤, at least in MCF-7/SR Ϫ cells, because MLT had no effect on p38 phosphorylation as examined in the circadiancomplete tissue-isolated MCF-7/SR Ϫ xenograft nude rat perfusion model (Fig. 1C) . However, p38 may be involved in MLT's regulation of GSK3␤ in other cell lines. We further demonstrated that MLT activation of GSK3␤ leads to reduced intracellular levels of ␤-catenin, as well as repression of the ␤-catenin/TCF/LEF-mediated transcription (Fig. 3) . MLT was able to repress not only the basal TOP-FLASH activity but also the TOP-FLASH activity induced by ␤-catenin overexpression. The greatest effect of MLT on inhibiting TOPFLASH transcription was observed with the elevated expression of the MT 1 MLT receptor (Fig. 3C) , suggesting that MT 1 receptor is important in driving this process. The MT 1 is a G protein-coupled receptor that has been shown to couple to various G proteins (G␣ i2 , G␣ i3 , G␣ q , and G␣ 11 ) (33) . Further studies are needed to determine the specific G␣ protein(s) to which MT 1 couples to regulate ␤-catenin. The involvement of MT 2 receptor was not examined, because we have previously shown that MT 2 is not expressed in MCF-7 breast cancer cell line (34). Ϫ cell migration in wound healing assays. Wounds were generated as described in Materials and Methods. Cells were treated with MLT (10 Ϫ8 M) or vehicle (Ctrl, 0.00001% ethanol.) for 48 h. Data are presented as % closure. Percent closure (%) ϭ migrated cell surface area/total surface area ϫ 100. *, P ϭ 0.0407 vs. diluent-treated cells by two-tailed student's t test (n ϭ 3). D, MLT inhibited the migration of MCF-7/SR Ϫ cells treated with MLT (10 Ϫ8 M) or vehicle (Ctrl, 0.00001% ethanol.) for 24 h in transwell assays. Data are presented as % of control (100%). *, P ϭ 0.00167 vs. diluent-treated cells by two-tailed student's t test (n ϭ 3). Data are mean Ϯ SEM. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; DAPI, 4Ј,6-diamidino-2-phenylindole.
The ability of MLT to regulate Akt, GSK3␤, and ␤-catenin led to our hypothesis that MLT plays an important role in the regulation of EMT. Thus, we further examined whether MLT alters EMT phenotypes. Key phenotypic changes in cells undergoing EMT include decreased expression of E-cadherin and increased expression of vimentin (2, 4) . Because parental MCF-7 cells express very low levels of vimentin protein, we used a MCF-7/caSrc clone (27) that exhibits EMT-like features, including low levels of E-cadherin and elevated levels of vimentin. MLT administration restored the expression of E-cadherin and suppressed the expression of vimentin in these cells (Fig. 4A) , which is indicative of an inhibitory effect on EMT. The effect of MLT on E-cadherin expression is mediated, at least partially, at the transcriptional level, because MLT increased the mRNA levels of E-cadherin as measured by real-time RT-PCR analyses (Supplemental Methods and Supplemental Fig. 2) . Thus, MLT, via blockade of Akt-mediated repression of GSK3␤ and decreased ␤-catenin levels/activity, regulates the expression of the EMT markers E-cadherin and vimentin. These results are consistent with the previous report by Cos et al. (19) , who showed that MCF-7 cells incubated with MLT (10 Ϫ9 M) exhibited elevated levels of E-cadherin as determined by immunohistochemistry.
The ability of MLT administration to alter subcellular localization of Ecadherin (Fig. 4B ) and significantly reduce the migration rate of MCF-7/SR Ϫ cells (Fig. 4, C and D) , the definitive phenotypic change associated with EMT, confirms that MLT, via the regulation of GSK3␤, represses EMT and inhibits the migratory behavior of breast cancer cells. It is important to note that although the maximal effects of MLT on the protein expression of EMT markers (E-cadherin and vimentin) were observed after 5 d of MLT administration (Fig. 4A) , we started to see changes in the mRNA levels of Ecadherin as early as 3 h (data not shown). The phenotypic changes (Ecadherin localization and cell migration) were observed within 48 h of treatment (Fig. 4, B-D) . Previous studies have demonstrated that MLT acts through multiple mechanisms to inhibit breast cancer cell invasion/metastasis, which include reinforcement of cell adhesion via increasing the expression of E-cadherin and ␤-integrin (19) , and suppression of the degradation of extracellular matrix via inhibiting p38 MAPK and its downstream targets MMP2 and MMP9 (18) . The regulation of GSK3␤ and EMT represents an additional mechanism underlying the antiinvasive/metastatic action of MLT.
MLT is a well-established output of the SCN, the central pace maker, whose production by the pineal gland is under circadian control (12) (13) (14) ; thus, it follows that phosphorylation/activity of Akt and GSK3␤, being regulated by MLT, should exhibit circadian-dependent daily Ϫ tumors were implanted in nude rats exposed to either control 12L:12D cycle (Ctrl) (upper panels) or light-at-night (12L:12L with a light intensity of 0.20 lux present at night, lower panels). Tumors were harvested at 4-h intervals over a 24-h period starting at ZT2. Levels of phospho-GSK3␤ (Ser 9 ) and total-GSK3␤ were determined by Western blot analysis. The experiment was done in triplicate. B, The band intensity of phospho-GSK3␤ (Ser 9 ) was quantified and normalized to that of total-GSK3␤. The data are expressed as percent phospho-GSK3␤ (ratio of phospho-GSK3␤ to total-GSK3␤). Each data point represents the average of three tumors. Error bars represent SD. C, Serum levels of MLT in the rat blood at ZT6 and ZT18 were measured by RIA assays. p-, Phospho-; t-, total-.
variations. Indeed, our collaborators have observed a circadian control of the phosphorylated Akt (Ser 473 ) in the tissue-isolated MCF-7/SR Ϫ xenografts, which peaked at midlight phase (ZT6), and were low during the dark phase (21) . Here, using the same MCF-7/SR Ϫ xenografts, we demonstrated that the phosphorylation of GSK3␤ (Ser 9 ) also displays a circadian rhythm, with a peak at midlight phase (ZT6) and a nadir at middark phase (ZT18) (Fig. 5, A and B) . The peak levels of GSK3␤ phosphorylation (Ser 9 ) were detected at the same time as Akt phosphorylation (21) . It is important to note that based on the circadian rhythm of its phosphorylation at the Ser 9 inhibitory site, GSK3␤ activity is suppressed during the light phase (ZT2-10) and up-regulated during the dark phase (ZT14 -ZT22) in presence of high circulating MLT levels (Fig. 5C ). In contrast, circadian disruption by exposure of the host animal to light-at-night almost completely abolished the nocturnal MLT surge (9.6 Ϯ 0.3 vs. 84 Ϯ 6.0 pg/ml in 12L:12D at ZT18) (Fig. 5C ) and dysregulated the circadian rhythm of GSK3␤ phosphorylation (Fig. 5, A and B) , resulting in dark phase levels of Ser 9 -phosphorylated GSK3␤ elevated to the daytime high levels. The ability of blood from women receiving MLT supplementation to suppress the daytime levels of Akt phosphorylation (Fig. 1B) clearly demonstrates its role in regulating GSK3␤ phosphorylation and activity. Because dim light-at-night appears to specifically disrupt MLT rhythm (20) , these data suggest that the circadian regulation of GSK3␤ phosphorylation is mediated through MLT.
Next, we examined whether the circadian rhythmic activity of GSK3␤ induced circadian regulation in the levels of its target gene Snail. Snail is a direct substrate of the kinase activity of GSK3␤ (8) . Meanwhile, it is also an indirect target of GSK3␤ via the ␤-catenin-mediated transcriptional regulation (6) . The protein levels of Snail exhibit a very pronounced circadian rhythm in MCF-7/SR Ϫ xenografts (Fig.   6 ). Interestingly, the peak levels of Snail protein were detected at the middark phase (ZT18) when GSK3␤ is most active, which then began to fall at the late-dark phase (ZT22) and reached its nadir at the early-light phase (ZT2). The 8-h lag period observed between the start of the up-shift of GSK3␤ activity (ZT14) and the start of down-shift of Snail levels (ZT22), as well as that observed between the peak of GSK3␤ activity (ZT18) and the nadir of Snail levels (ZT2), may reflect a delayed response due to the GSK3␤/␤-catenin-mediated transcriptional/translational processing. This may seem paradoxical as the Snail protein has a short half-life controlled by GSK3␤-directed ubiquitination/degradation (8) . A potential explanation for this paradox is that GSK3␤ is a unique kinase whose phosphorylation of substrates requires a priming phosphorylation by another kinase (5). In the case of Snail, it has been reported that a "priming" phosphorylation by CK1 is essential for the subsequent GSK3␤ phosphorylation (35) . Thus, the rhythm of Snail protein expression driven by the posttranslational control mechanism alone may potentially be determined by three factors: rhythm of GSK3␤ activity, rhythm of CK1 activity, and the availability/proportion of the primed pool of Snail protein at a given time. Given the complex nature of the control mechanism underlying Snail expression, it is plausible that the pattern of Snail's circadian rhythm may not necessarily follow that of GSK3␤. Further support of a circadian regulation of Snail is seen as exposure of the host animal to light-at-night almost completely abolishes the circadian rhythm of Snail protein expression (Fig. 6) .
Breast cancer incidence is five times higher in industrialized nations characterized by excessive usage of artificial light during the night vs. underdeveloped countries (36) , and it has been hypothesized that exposure to lightat-night via its suppression of nocturnal MLT production (13) may represent a unique risk factor for breast cancer in industrialized countries (37) . Recently, night shift work, and ostensibly exposure to light-at-night, has been designated by the World Health Organization as a probable (group 2A) carcinogen (38) . A major unanswered question is how circadian disruption influences cell proliferation in tumors, as well as other aspects of tumor progression, including invasion/metastasis. We have previously reported that exposure to light-at-night induces suppression of nocturnal MLT, stimulating breast tumor fatty acid uptake and metabolism and activating the insulin-like growth factor-I receptor/phosphoinositide-dependent protein kinase 1 signaling pathway, promoting breast tumor growth in vivo (20, 21) . In the present studies, we further demonstrated that exposure of human subjects to light-at-night disrupts the normal regulation of the Akt/GSK3␤ axis by MLT in human PC3 prostate xenograft tumors (Fig. 7) . Altogether, these results indicated that light-at-night-induced disruption of the MLT circadian rhythm has significant and far-reaching biological consequences. In these studies, we also present our data from PC3 human prostate cancer xenografts, because we have observed similar inhibitory effects of MLT on the phosphorylation of Akt and GSK3␤ and other kinases in prostate cancer cells as well as in breast cancer cells (data not shown). Our data in PC3 human prostate cancer xenografts supports our hypothesis that light-atnight-induced disruption of MLT circadian rhythm has a major impact on the normal regulation of Akt and GSK3␤ by MLT and that MLT regulation of Akt and GSK3␤ occurs in multiple cancers, ruling out the possibility of MLT's actions being cell line or tumor type specific. Moreover, the data generated in the PC3 xenograft model demonstrate that MLT's regulation of Akt and GSK3␤ may impact the invasive capacity of a number of malignancies, including breast and prostate cancer.
FIG. 7.
Exposure to light-at-night in human male subjects induces disregulation of Akt and GSK3␤ phosphorylation in human prostate cancer. A, Separate sets of two tissue-isolated PC3 human prostate cancer xenografts were perfused with human venous blood drawn from male human subjects during the daytime, nighttime, and nighttime after 90 min of ocular, bright, white light exposure at 580 W/cm 2 (i.e. 2800 lux) (light-at-night). Western blot analyses examined the phosphorylation of Akt and GSK3␤. B, The band intensity of phospho-Akt and phospho-GSK3␤ was quantified and normalized to that of total-Akt and total-GSK3␤, respectively. The data are expressed as percent phospho-Akt and GSK3␤. Each data point represents the average of two tumors. n ϭ 3; *, P Ͻ 0.05; **, P Ͻ 0.01 (ANOVA with Student-Newman-Keuls post hoc test). Error bars represent SEM. p-, Phospho-; t-, total-. In summary, our findings demonstrate the existence of a circadian rhythm in GSK3␤ phosphorylation/activity in human breast cancer orchestrated by the central circadian pacemaker via its output, MLT. It has been previously reported that the GSK3␤ activity displays a 24-h cycle in the SCN and liver (39) . Disruption of the GSK3␤ circadian rhythm has the potential to cause major perturbations in the regulation of breast cancer EMT and metastasis via deregulation of ␤-catenin target genes, such as Snail and the Snail-related zinc-finger transcription factor, Slug. Given that many GSK3␤ substrates, including c-Myc, Cyclin D1, ␤-catenin, and the recently identified coactivator steroid receptor coactivator-3 (5, 40 -42) , function as protooncogenes, it becomes clearer that exposure to light-at-night, via its suppression of MLT and disruption of GSK3␤'s rhythm of phosphorylation/activity, contributes to the increased breast cancer risk observed in rotating night shift workers (43) . Furthermore, given that MLT's actions on GSK3␤ and E-cadherin mRNA expression happen within hours, the repression of nighttime MLT by light-at-night, and the subsequent upregulation of Akt activity and down-regulation of GSK3␤ activity, may potentially drive EMT of breast cancer cells and increase the metastatic spread of breast cancer among high-risk individuals, including breast cancer patients occupationally exposed to light-at-night and elderly breast cancer patients who display sleep disruption that involves light-at-night-induced MLT suppression.
The primary goal of this study is to understand the molecular basis for the association between circadian disruption and breast cancer. We believe that these data support the association between light-at-night-induced circadian disruption and the increased breast cancer risk: light-at-night disrupts the circadian rhythm of GSK3␤ via perturbation of the nocturnal surge of MLT, the biological timing signal. Our findings also link the circadian clock, which imposes a temporal regulation of many physiological functions, to the GSK3␤ pathway, which is a key gatekeeper of EMT.
